Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Le Du

Showing results (281-290 of 309) with videos related to

Pageof 31
Sort By:
Breast Cancer Research and Treatment|October 23, 2021
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancerPauline Corbaux, Audrey Lardy-Cleaud, Marie Alexandre, et al.
Diagnostic and Interventional Imaging|May 13, 2025
The continued industrial use of ethylene oxide despite health risks: An interventional radiology perspective on a broader medical challenge of balancing sterility, safety, and sustainabilityJulien Ognard, Marie Schmidt, Christophe Paya, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 20, 2024
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani, et al.
Eclinicalmedicine|November 18, 2020
Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher studyBruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2019
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroupVéronique D'Hondt, Jean-Luc Canon, Lise Roca, et al.
Neuroimage|February 7, 2021
Association of quality of life with structural, functional and molecular brain imaging in community-dwelling older adultsValentin Ourry, Julie Gonneaud, Brigitte Landeau, et al.
The Oncologist|August 17, 2023
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME ProgramFanny Le Du, Matthieu Carton, Thomas Bachelot, et al.
EMBO Molecular Medicine|March 24, 2018
Human ALPI deficiency causes inflammatory bowel disease and highlights a key mechanism of gut homeostasisMarianna Parlato, Fabienne Charbit-Henrion, Jie Pan, et al.
Molecular Cell|January 18, 2016
TRF2-Mediated Control of Telomere DNA Topology as a Mechanism for Chromosome-End ProtectionDelphine Benarroch-Popivker, Sabrina Pisano, Aaron Mendez-Bermudez, et al.
Cell Chemical Biology|September 24, 2019
Design on a Rational Basis of High-Affinity Peptides Inhibiting the Histone Chaperone ASF1May Bakail, Albane Gaubert, Jessica Andreani, et al.
Pageof 31

Showing results (281-290 of 309) with videos related to

Sort By:
Pageof 31
Breast Cancer Research and Treatment|October 23, 2021
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancerPauline Corbaux, Audrey Lardy-Cleaud, Marie Alexandre, et al.
Diagnostic and Interventional Imaging|May 13, 2025
The continued industrial use of ethylene oxide despite health risks: An interventional radiology perspective on a broader medical challenge of balancing sterility, safety, and sustainabilityJulien Ognard, Marie Schmidt, Christophe Paya, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 20, 2024
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani, et al.
Eclinicalmedicine|November 18, 2020
Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher studyBruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2019
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroupVéronique D'Hondt, Jean-Luc Canon, Lise Roca, et al.
Neuroimage|February 7, 2021
Association of quality of life with structural, functional and molecular brain imaging in community-dwelling older adultsValentin Ourry, Julie Gonneaud, Brigitte Landeau, et al.
The Oncologist|August 17, 2023
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME ProgramFanny Le Du, Matthieu Carton, Thomas Bachelot, et al.
EMBO Molecular Medicine|March 24, 2018
Human ALPI deficiency causes inflammatory bowel disease and highlights a key mechanism of gut homeostasisMarianna Parlato, Fabienne Charbit-Henrion, Jie Pan, et al.
Molecular Cell|January 18, 2016
TRF2-Mediated Control of Telomere DNA Topology as a Mechanism for Chromosome-End ProtectionDelphine Benarroch-Popivker, Sabrina Pisano, Aaron Mendez-Bermudez, et al.
Cell Chemical Biology|September 24, 2019
Design on a Rational Basis of High-Affinity Peptides Inhibiting the Histone Chaperone ASF1May Bakail, Albane Gaubert, Jessica Andreani, et al.
Pageof 31